Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: Results from the TORTUGA trial

RheumatologyMaksymowych WP, Østergaard M, Landewé R, et al. | October 19, 2021


Filgotinib treatment for ankylosing spondylitis (AS) provided significant decreases in magnetic resonance imaging (MRI) measures of spinal inflammation, including in vertebral bodies, facet joints, and posterolateral elements, compared with placebo.

  • In this post-hoc analysis of the TORTUGA trial [AS patients were treated with filgotinib 200 mg (n = 58) or placebo (n = 58) once daily for 12 weeks], spine MRIs from 47 filgotinib- and 41 placebo-treated patients were assessed.

  • There were no significant differences for corner or non-corner vertebral body inflammation subscores, spine fat lesion, bone erosion, or new bone formation (NBF) scores.

  • A positive correlation between change from baseline in total inflammation score and SPARCC (Spondyloarthritis Research Consortium of Canada) spine score was identified in the filgotinib group.

  • A correlation of baseline NBF scores with baseline BASMI (Bath Ankylosing Spondylitis Metrology Index) but not with BASFI (Bath Ankylosing Spondylitis Functional Index) scores was evident.

Read the full article on Rheumatology